As RNA-based therapeutics continue to revolutionize modern medicine, lipid nanoparticles (LNPs) have emerged as the leading delivery system for mRNA and other nucleic acids. However, the journey from laboratory-scale research to GMP-compliant production is far from straightforward. Robust, scalable, and reproducible processes are essential to ensure high-quality drug products ready for clinical trials and beyond.
In this new article , we explore the key steps and technologies that Curapath employs to optimize the LNP formulation process and deliver high-quality, GMP-compliant products
The Four Pillars of LNP Manufacturing
- Microfluidics-Based Formulation
At the heart of LNP production lies the Knauer NanoScaler, employing Impingement Jets Mixing (IJM) technology. This advanced system ensures precise control over LNP size (80–120 nm) and polydispersity index (PDI), delivering exceptional reproducibility from R&D to clinical batch production. This technology has been a critical tool in scaling up formulations, including those used for SARS-CoV-2 vaccines. - Tangential Flow Filtration (TFF) Purification
Purification is a critical step in ensuring the final product meets stringent quality standards. Using 100 kDa MWCO TFF cassettes, Curapath removes impurities and residual ethanol efficiently, achieving consistent results across scales. With a diafiltration volume optimized for ethanol removal, TFF enables uninterrupted processing and precise control over final LNP purity and API concentration. - Sterile Filtration and Fill & Finish Activities
Sterile Filtration and Fill & Finish Activities
Sterility is paramount in drug manufacturing. Curapath’s advanced DP GMP facilities employ double sterilizing filters (0.20 µm) and aseptic filling systems to ensure unparalleled product quality. Each batch is filled into 10 mL vials or custom volumes under Grade A laminar flow conditions, with personalized labeling and regulatory support tailored to customer needs for clinical trials. - Process Control and Characterization
A robust array of analytical techniques is integrated throughout the formulation process. These include:
- Dynamic Light Scattering (DLS): Monitoring LNP size and PDI.
- HPLC-CAD: Analyzing lipid composition and purity.
- UV-Vis Spectroscopy: Measuring mRNA content.
- Fluorescence Assays (RiboGreen): Assessing encapsulation efficiency.
- Automated Gel Electrophoresis (AGE): Ensuring mRNA integrity.
Why Robust Processes Matter
LNP formulations are sensitive to variations in manufacturing and purification. Without precise control, deviations can compromise drug efficacy or safety. Curapath’s vertically integrated approach ensures seamless scaling from lab to clinical batches, meeting the highest GMP standards while maintaining flexibility to adapt to client needs.
Conclusion
As a trusted partner in non-viral gene therapy, Curapath combines cutting-edge technology with deep expertise to deliver high-quality LNP formulations. By mastering each stage of the Lnp GMP manufacturing process, from formulation to fill and finish, Curapath supports clients in their journey from preclinical development to commercial launch.
If you want to know more abour Curapath Lnp formulation process yo can reach out or donwload the full article here
👇👇👇👇
Full App Note
Lnp GMP manufacturing
